Latest News

UCB psoriasis drug beats J&J’s second top-selling product in Phase III study

Psoriasis Diagnosis, Medical Concept. Composition of Medicaments

Results of the BE VIVID study showed that UCB’s bimekizumab showed a statistically significant improvement in skin clearance compared with J&J’s Stelara and placebo.

Source link

Related posts

United States Ovarian Cancer Market and Competitive Landscape 2014-2018 & 2019-2024 – ResearchAndMarkets.com

Newsemia

Medical News Today: How to speed up recovery from a cesarean delivery

Newsemia

Medical News Today: What are the symptoms of pneumococcal disease?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World